Get started
Author

Felix Sebastian Lichtenegger

Observed names: F S Lichtenegger, F. S. Lichtenegger, F.S. Lichtenegger, FS Lichtenegger, Felix Lichtenegger, Felix S Lichtenegger, Felix S. Lichtenegger, Lichtenegger, Felix, Lichtenegger, Felix S.
Observed institutions: Roche (Switzerland), German Cancer Research Center, Center for Integrated Protein Science Munich, Universität Ulm, Helmholtz Munich, LMU Klinikum, Roche Pharma AG (Germany), Deutsches Konsortium für Translationale Krebsforschung, Case Western Reserve University, Ludwig-Maximilians-Universität München
ORCID: 0000-0003-3990-1802
Observed ORCID: 0000-0003-3990-1802
OpenAlex ID: A5089965167
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
2018 · S. Haubner, F. Perna, et al. · Leukemia · 336
PDF
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
2015 · C Krupka, P Kufer, et al. · Leukemia · 253
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330
2013 · Christina Krupka, Peter Kufer, et al. · Blood · 208
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
2018 · Felix S. Lichtenegger, Maurine Rothe, et al. · Frontiers in Immunology · 179
PDF
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
2015 · Frauke M. Schnorfeil, Felix S. Lichtenegger, et al. · Journal of Hematology & Oncology · 148
PDF
Recent developments in immunotherapy of acute myeloid leukemia
2017 · Felix S. Lichtenegger, Christina Krupka, et al. · Journal of Hematology & Oncology · 131
PDF
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
2024 · Ignacio Melero, Maria de Miguel Luken, et al. · Nature · 128
PDF
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2 , BCR‐JAK2 and ETV6‐ABL1 fusion genes
2020 · Juliana Schwaab, Nicole Naumann, et al. · American Journal of Hematology · 75
PDF
Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
2019 · Heleen H. Van Acker, Maarten Versteven, et al. · Journal of Clinical Medicine · 73
PDF
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
2021 · Christian Augsberger, Gerulf Hänel, et al. · Blood · 70
CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells
2012 · Felix S. Lichtenegger, Katharina Mueller, et al. · PLoS ONE · 69
PDF
Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD 200
2017 · Thomas Köhnke, Veronika K. Wittmann, et al. · British Journal of Haematology · 65
PDF
Cellular Uptake of Tile-Assembled DNA Nanotubes
2014 · Samet Kocabey, Hanna Meinl, et al. · Nanomaterials · 64
PDF
MBP-PLP fusion protein-induced EAE in C57BL/6 mice
2006 · Stefanie Kuerten, Felix S. Lichtenegger, et al. · Journal of Neuroimmunology · 54
Immunotherapy for Acute Myeloid Leukemia
2015 · Felix S. Lichtenegger, Christina Krupka, et al. · Seminars in Hematology · 50
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
2019 · Michael Ruzicka, Lars M. Koenig, et al. · Leukemia · 49
PDF
New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
2014 · Marion Subklewe, Christiane Geiger, et al. · Cancer Immunology Immunotherapy · 45
PDF
Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission
2011 · Barbara Beck, Daniela Dörfel, et al. · Journal of Translational Medicine · 41
PDF
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
2020 · Felix S Lichtenegger, Frauke M Schnorfeil, et al. · Clinical & Translational Immunology · 39
PDF
Targeting CD157 in AML using a novel, Fc-engineered antibody construct
2017 · Christina Krupka, Felix S. Lichtenegger, et al. · Oncotarget · 33
PDF
Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML
2014 · Felix S. Lichtenegger, Robin Lorenz, et al. · Leukemia Research · 32
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens
2021 · Gerulf Hänel, Caroline Angerer, et al. · Cancer Immunology Immunotherapy · 22
PDF
Current Strategies in Immunotherapy for Acute Myeloid Leukemia
2012 · Felix S Lichtenegger, Frauke M Schnorfeil, et al. · Immunotherapy · 22
1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
2020 · I. Melero, M.F. Sanmamed, et al. · Annals of Oncology · 18
PDF
Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade
2016 · Felix S. Lichtenegger, Katrin Deiser, et al. · Blood · 9
Works count: 64
Citation count: 2,282
H-index: 22
I10-index: 24
Year
Topic
Type